CRD-A vs JPM
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
CRD-A exhibits significant valuation misalignment, trading at $10.84 despite a Graham Number of $5.58 and an Intrinsic Value of $2.73. While the Piotroski F-Score of 4/9 indicates stable health, this is offset by razor-thin profit margins (1.55%) and negative revenue growth (-11.20% YoY). The technical trend is completely bearish (0/100), and the high dividend payout ratio (74.36%) is unsustainable given the current earnings contraction. Overall, the stock appears heavily overvalued relative to its fundamental deterministic baselines.
JPM exhibits a concerning Piotroski F-Score of 2/9, indicating weak short-term fundamental health, and currently trades at a significant premium to both its Graham Number ($239.11) and Intrinsic Value ($140.07). While the company maintains a strong ROE of 16.13% and dominant market positioning, negative YoY earnings growth (-3.60%) and bearish insider activity from the CEO and CFO signal internal caution. The stock's current price of $313.68 suggests the market is pricing in a growth premium that is not currently supported by the deterministic health or value metrics.
Compare Another Pair
Related Comparisons
CRD-A vs JPM: Head-to-Head Comparison
This page compares Crawford & Company (CRD-A) and JPMorgan Chase & Co. (JPM) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.